Potential risk of ramucirumab-induced liver failure associated with prior use of oxaliplatin in patients with metastatic gastric cancer: a case report

• 발행기관: 조선대학교 의학연구원
• 저자명: Sang Hun Lee Young Jin Choi Young Mi Seol
• 간행물 정보: 『Medical Biological Science and Engineering』제8권 제1호, 33~39쪽, 전체 7쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2024.12.31

국문 초록

In inoperable gastric cancer, anti-angiogenic therapy with ramucirumab in combination with paclitaxel has been widely used for patients who have progressed after first-line platinum and fluoropyrimidine doublet chemotherapy. Unless underlying hepatic dysfunction exists, the incidence of ramucirumab-related hepatic toxicity is extremely low. However, prior use of a hepatotoxic anticancer drug may trigger liver injury, resulting in ramucirumab-induced hepatic failure. Herein, we report a case of metastatic gastric cancer treated with second-line ramucirumab and showed signs of hepatic encephalopathy. The patient had no definite evidence of hepatic dysfunction at the start of treatment, and was previously treated with first line oxaliplatin-combined chemotherapy. It was assumed that the deteriorated hepatic environment from oxaliplatin treatment may have led to ramucirumab-induced hepatic injury. Since selecting ramucirumab as a sequential therapy after use of oxaliplatin is a standard of care, it is important to monitor signs of hepatic failure during use of ramucirumab.

목차

INTRODUCTION

CASE REPORT

DISCUSSION

REFERENCES

키워드

Stomach neoplasms Ramucirumab Oxaliplatin Liver failure